CAMBRIDGE, Mass. - July 6, 2001 – With the help of two technology companies, Cambridge Technology Enterprises (CTE) Inc., the commercial arm of CellExchange Inc., and eHealthWare, Pfizer Inc. has successfully automated its clinical drug trial procedures, which will result in reduced development costs and time to market. In recognizing that its manual drug trial processes were cumbersome and could be streamlined by entering the digital age, the company enlisted the help of eHealthWare, Inc. (eHW), and Cambridge Technology Enterprises Inc. to create and implement a software solution.

It takes on average $350 to $500 million and eight to ten years for a drug to come to market, and much of that time and money is absorbed by clinical trials. The traditional, paper-based system used for recording, compiling and processing clinical trial data is unable to support the growing volume of information required of today's clinical trials. eHealthWare and CTE worked closely with Pfizer to fully gauge the complexities of every stage of its trials. The companies were able to immediately identify how computer technology could make Pfizer’s processes more efficient.

CTE specializes in Urgentware – software that helps businesses resolve time-critical problems -- as well as solutions that work with customers’ existing systems to significantly improve their operations. For Pfizer, eHealthWare and CTE built a customized application that would work with its existing enterprise systems to:

• Automatically collect results of drug trials from each Pfizer office and subsidiary
• In real-time, assimilate that data into a central analysis and reporting repository
• Validate the data by cross-referencing it with standards built into the software
• Use intelligent agents to detect problems through user-defined rules, alert criteria and escalation procedures
• Create automatic notifications about the status of the process (e.g. failure, success, etc.)
• Automate the report generation and distribution process
• Enable users to identify, isolate and recover from problems in real-time using wireless devices

“Automating certain aspects of the clinical drug trial process results in a remarkable reduction in time to market and drug development costs,” says Himanshu Raval, Pfizer Senior Manager, Global Business Technology. “It will reduce costs, but on a broader level, it will provide us with a way to significantly expedite our development processes, increasing the numbers of medications we can provide to a public that is more and more in need of them.”

“With the software solution, Pfizer expects that each clinical drug trial will take less time and money,” continued Raval. “Time to market will be decreased, thus enhancing the revenue potential for each pharmaceutical.”

eHealthWare, Inc. (www.ehealthware.com) develops software applications and provides related support services to the pharmaceutical, biotechnology and medical devices industries. It is located in Massachusetts.

Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world's best-known consumer products. Pfizer had global revenues of $29.6 billion in 2000.

About Cambridge Technology Enterprises Inc.
Cambridge Technology Enterprises (CTE), a CMMI Level 5 next-generation business lifecycle solutions provider, has a focus on building and integrating business applications. CTE’s core competency lies in its collaborative delivery model, a solution delivery approach that aligns business, technical, and user stakeholders; includes partner technologies and services as necessary; and delivers end-to-end solutions on a fixed price and fixed time frame basis.

CTE’s business model is based on a global delivery model foundation, which stays close to the customer and yet optimizes the value of the solution offered.


For more information, please visit www.ctepl.com, or e-mail us at info@ctepl.com.